Tatva Chintan Pharma Chem
- Market cap
- ₹ 3,677 Cr.
- P/E
- 57.4x
- P/B
- 4.98x
- 52-week range
- 1,044.1 – 2,113.6
- ROE
- 6%
- ROCE
- 7%
- Dividend yield
- 0.1%
- Debt / equity
- 0.15
- Sector
- Chemicals & Petrochemicals
- Industry
- Specialty Chemicals
- Listed on
- NSE, BSE
About
Tatva Chintan Pharma Chem Limited is an India-based specialty chemical manufacturing company. The Company is primarily engaged in manufacturing, sale and distribution of specialty chemicals, phase transfer catalysts (PTC), structure directing agents (SDA), electrolyte salts and solutions (ESS), pharmaceutical and agrochemical intermediates and other specialty chemicals (PASC). It operates in the Specialty chemical segment. Its SDA is a high purity quaternary salt, which plays a role in forming channels during the synthesis of zeolites. PTC acts as a catalyst in chemical reactions, facilitating reactions between reactants of different phases. Its products serve various sectors, including automotive, refinery, pharmaceutical, agrochemicals, paints and coatings, dyes and pigments, personal care, and flavors and fragrances. The Company operates two manufacturing facilities situated at Ankleshwar and Dahej in Bharuch, Gujarat, India.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Specialty Chemicals: 130 companies →Tatva Chintan Pharma Chem against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)57.4 against a typical 26.3: pricier than most peers (1st = cheapest).102nd of 129
- Sales growth+75% against a typical +25.9% from a year earlier.12th of 112
- Profit growth+110% against a typical +42.4% from a year earlier.30th of 102
- Share price, 3 months−8.3% against a typical −6.1%.67th of 118
- Size₹ 3,677.5 Cr. market value against a typical ₹ 359.6 Cr. (1st = largest).28th of 126
Latest announcements
Exchange filings and their impact on the company.
- Blockbuster H1 with revenue up 60% and PAT more than doubled points to ~50% higher sales and profits over next 12 months.
Tatva Chintan reported strong Q2 FY27 results with consolidated revenue of Rs 217.3 crore, up 76% from last year, and net profit of Rs 21.5 crore, more than double last year. For the first half, revenue was Rs 384.4 crore and profit was Rs 37.4 crore, already close to last full year's profit of Rs 42.1 crore. The growth has increased working capital and short-term borrowings, but overall it points to much higher sales and earnings over the next year.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety
Rated A- by CRISIL- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Crisil A- | Stable | 8 Sep 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 8 Sep 2026 | ▲ Upgrade | Crisil A- | — | CRISIL | ₹ 245 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 19 Oct 2026 | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 17 Jul 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 16 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and dividend, if any. |
| 21 Jan 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 31 Oct 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 24 Jul 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 84 | 98 | 105 | 83 | 86 | 108 | 117 | 124 | 131 | 134 | 167 | 217 |
| Expenses | 73 | 83 | 93 | 78 | 79 | 99 | 100 | 101 | 106 | 106 | 135 | 177 |
| Operating Profit | 11 | 16 | 13 | 6 | 7 | 9 | 17 | 22 | 25 | 28 | 32 | 41 |
| OPM % | 13% | 16% | 12% | 7% | 8% | 8% | 15% | 18% | 19% | 21% | 19% | 19% |
| Other Income | 1 | 5 | 1 | 0 | 0 | 1 | 1 | 1 | 2 | 0 | 1 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 3 |
| Depreciation | 7 | 6 | 7 | 7 | 7 | 7 | 9 | 9 | 9 | 10 | 11 | 11 |
| Profit before tax | 5 | 14 | 7 | −1 | 0 | 2 | 9 | 14 | 18 | 17 | 21 | 29 |
| Tax % | 34% | 30% | 24% | −34% | −165% | 49% | 27% | 27% | 14% | 38% | 24% | 26% |
| Net Profit | 3 | 10 | 5 | −1 | 0 | 1 | 7 | 10 | 15 | 10 | 16 | 21 |
| EPS in Rs | 1.48 | 4.11 | 2.23 | −0.28 | 0.06 | 0.44 | 2.84 | 4.24 | 6.49 | 4.41 | 6.83 | 9.17 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 11%
- 3 Years
- 6%
- TTM
- 50%
- 10 Years
- —
- 5 Years
- −4%
- 3 Years
- −5%
- TTM
- 260%
- 10 Years
- —
- 5 Years
- −5%
- 3 Years
- 4%
- TTM
- —
- 10 Years
- —
- 5 Years
- 8%
- 3 Years
- 4%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Tatva Chintan Pharma Chem | ₹ 1,634.90 | ₹ 3,677 Cr. | 57.4x | 5x | 6% | — |
| Asian Paints | ₹ 2,305.00 | ₹ 2,21,095 Cr. | 58.1x | 12.1x | 21.2% | 12.4% |
| Solar Industries India | ₹ 18,320.00 | ₹ 1,65,778 Cr. | 99.6x | 26.6x | 31.4% | 17.7% |
| Pidilite Industries | ₹ 1,514.00 | ₹ 1,54,107 Cr. | 64.8x | 14.7x | 23.8% | 16.9% |
| SRF | ₹ 2,309.00 | ₹ 68,444 Cr. | 44.6x | 6.1x | 13.8% | 11.6% |
| Linde India | ₹ 5,697.00 | ₹ 48,586 Cr. | 110.5x | 14.2x | 13.6% | 21.7% |
Management
- Chintan Nitinkumar Shah
- Executive Chairman of the Board, Managing Director
- Ajesh Kumar Mohanan Pillai
- Chief Financial Officer
- Ishwar Nayi
- Compliance Officer, Company Secretary
- Ajaykumar Mansukhlal Patel
- Whole Time Director
- Shekhar Rasiklal Somani
- Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.